Drug Trial Radar · NCT04622319
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
Last checked: Nov 19, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,600
Planned (sponsor's estimate)
Start
Dec 4, 2020
Primary completion
Jul 2, 2025
Study completion Jun 20, 2028
Sponsor
- Lead sponsor
- Daiichi SankyoDaiichi Sankyo (DSNKY)
- Sponsor type
- Industry
- Collaborators
- AstraZeneca; NSABP Foundation Inc; GBG Forschungs GmbH; Spanish Breast Cancer Research Group
- First posted
- Nov 9, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Patients with HER2-positive primary breast cancer (BC) who do not achieve complete response after appropriate neoadjuvant therapy are at higher risk of disease recurrence. More effective treatment options are needed for this patient population. This study will examine the efficacy and safety of trastuzumab deruxtecan (T-DXd) compared with trastuzumab emtansine (T-DM1) in high-risk patients with residual invasive breast cancer following neoadjuvant therapy.
Conditions
- HER2-Positive Primary Breast Cancer
- Residual Invasive Breast Cancer
Interventions
DS-8201aDrug
Administered initially as an intravenous (IV) infusion at a dose of 5.4 mg/kg on Day 1 of each 21-day cycle
T-DM1Drug
Administered initially as an intravenous (IV) infusion at a dose of 3.6 mg/kg on Day 1 of each 21-day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Invasive Disease-free Survival (IDFS) in Participants Who Were Administered Trastuzumab Deruxtecan (T-DXd) Compared With Trastuzumab Emtansine (T-DM1) TreatmentTime frame: Randomization to date of invasive local, axillary or distant recurrence, invasive contralateral breast cancer or death from any cause (whichever occurs first), up to approximately 57 months postdose
Locations
482 sites in 31 countries. Site status is shown where the registry gives one.
The Oncology Institute of Hope & Innovation
Anaheim, California
Kaiser Permanente
Anaheim, California
Kaiser Permanente
Baldwin Park, California
Kaiser Permanente
Bellflower, California
Kaiser Permanente
Fontana, California
Orange Coast Blood and Cancer Care
Fountain Valley, California
Kaiser Permanente
Harbor City, California
Kaiser Permanente
Irvine, California
Long Beach Memorial TCI
Long Beach, California
Kaiser Permanente
Los Angeles, California
Kaiser Permanente
Ontario, California
Kaiser Permanente
Panorama City, California
Kaiser Permanente
Riverside, California
Kaiser Permanente
San Diego, California
Kaiser Permanente
San Marcos, California
Kaiser Permanente
West Los Angeles, California
Kaiser Permanente
Woodland Hills, California
SCRI FCS North- Altamonte
Altamonte Springs, Florida
SCRI FCS South- Bonita
Bonita Springs, Florida
SCRI FCS North- Brandon Cancer Center
Brandon, Florida
SCRI FCS South- North Fort Myers
Cape Coral, Florida
SCRI FCS North- Mease/Clearwater
Clearwater, Florida
SCRI FCS South
Fort Myers, Florida
SCRI FCS South- Colonial
Fort Myers, Florida
SCRI FCS South- Gladiolus
Fort Myers, Florida
SCRI FCS North- Gainesville Cancer Center
Gainesville, Florida
Baptist MD Anderson Cancer Center
Jacksonville, Florida
SCRI FCS North- Villages East
Lady Lake, Florida
SCRI FCS South- Lakewood Ranch
Lakewood Rch, Florida
SCRI FCS North- Largo/Highland
Largo, Florida
SCRI FCS North- Lecanto
Lecanto, Florida
SCRI FCS South- Naples West
Naples, Florida
SCRI FCS South- Naples/Goodlette
Naples, Florida
SCRI FCS North- New Port Richey
New Port Richey, Florida
SCRI FCS North- Ocala
Ocala, Florida
Orlando Health
Ocoee, Florida
SCRI FCS North- Orange City
Orange City, Florida
Orlando Health
Orlando, Florida
SCRI FCS North- Orlando Downtown
Orlando, Florida
SCRI FCS South- Port Charlotte
Port Charlotte, Florida
Showing 40 of 482 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.